SEIZURES AND THEIR TREATMENTS IN ANGELMAN SYNDROME – LOUISVILLE 2019

Ron Thibert DO, MsPH Massachusetts General Hospital, Boston MA Harvard Medical School

Definitions

- Epilepsy is defined as 2 or more unprovoked seizures; recently modified to also include 1 unprovoked seizure with abnormal (epileptiform) EEG
- Seizure types describe the individual seizures
- Epilepsy syndrome constellation of seizure types, EEG findings and cognitive functioning

Seizure Types

Focal (Partial) Onset Seizures

- Arise from a small area on one side of the brain


Generalized Seizures

- Arise from large areas of cortex on both sides at the same time ("whole brain seizures")
- Secondarily generalized: begin as focal and then spread to the rest of the brain

Focal Seizure

and the second the sec

Generalized Seizure



Generalized Seizures

Epilepsies with or without developmental delays

- Generalized Tonic-Clonic
- Myoclonic
- Absence (typical)
- Epilepsies with developmental delays
 - Atonic
 - Absence (atypical)
 - Tonic
 - Spasms

Epilepsy syndromes

- Epilepsy syndromes are a constellation of various seizures types along with other clinical criteria
 - Seizure types
 - EEG findings
 - Cognitive functioning
- 2 epilepsy syndromes associated with AS
 - Lennox-Gastaut syndrome (common)
 - Myoclonic status in non-progressive encephalopathies (not common)

Lennox-Gastaut syndrome (LGS)

- Difficult to treat seizures of mixed types
 - Atonic
 - Tonic
 - Atypical absence
 - Can also have myoclonic, GTC or focal
- EEG findings: generalized slow spike and wave (<3 Hz)
- Cognitive dysfunction
- Many children with AS meet criteria for LGS Angelman syndrome is a genetic syndrome (UBE3A is the gene causing the symptoms; LGS is an epilepsy syndrome describing the epilepsy

Slow spike and wave in LGS



Myoclonic Status in Non-Progressive Encephalopathies

- Newer ILAE classification seizure syndrome
- Classified as an epileptic encephalopathy
- Characterized by sustained episodes of myoclonus with preserved consciousness but typically some regression
- Typically begins in early childhood
- Very rare but as many as 40% of reported cases are children with Angelman syndrome

STATUS EPILEPTICUS AND NON-CONVULSIVE STATUS EPILEPTICUS (NCSE)

Status Epilepticus

- Definition:
 - Seizures lasting greater than 10-15 minutes or frequent seizures with no return to baseline between events (definitions for status range from 5-30 minutes)
 - Prevalence varied but not common in AS
 - If this does occur in AS, there is usually a trigger such as infection

NCSE

Non-convulsive status epilepticus (NCSE)

- Occurs in 50-90% with AS (MGH clinic ~20%)
- Episodes of decreased alertness lasting days to weeks often with loss of skills
- Typical seizures usually lessen during NCSE
- AS not progressive so always consider NCSE first if any regression
- Most commonly absence status
- Frequent myoclonic jerks in this setting could be myoclonic status in non-progressive encephalopathies (MSNE) – rare but AS most common etiology

NCSE EEG



EPILEPSY IN ANGELMAN SYNDROME

Seizures in Angelman syndrome

Epilepsy in Angelman syndrome is a generalized epilepsy


- Generalized tonic-clonic
- Atypical absence
- Atonic
- Myoclonic
- Tonic (rare)
- Spasms (rare if at all)
- Focal seizures present in ~30%

ASF Seizure Survey


Seizure survey performed in 2006-07

- On-line questionnaire through ASF
- 461 responses
 - 391 (86%) had seizures
 - 60% had multiple seizure types
 - >90% had some combination of generalized seizure types with or without focal seizures
 - ~30% reported focal seizures
 - Thibert et al., *Epilepsia* 2009

AS Seizure types



AS Seizures by subtype



Seizures in AS - Age

Seizures in AS relative to age:


- Average onset approximately 2-3 yrs of age, typically beginning in childhood; infrequent cases of seizures <1 year of age</p>
- Seizures are usually most frequent and most intense in early childhood and tend to improve by puberty
- Seizures can then return and persist into adulthood but are typically much less frequent and less intense – our phone survey of 110 adults with AS showed ~1/3 had seizures recur in adulthood (Larson et al. AJMG 2015); a more recent case series from our clinic of 53 adults showed ~27% still with seizures in adulthood – ~2/3 of those with seizures had them monthly or yearly/sporadic

EEG IN ANGELMAN SYNDROME

EEG in AS

- Over 90-95% have abnormal EEG patterns with or without clinical seizures
- Normal EEG's rare, but have been reported in some with imprinting center defects
- 3 common patterns
 - Bi-frontal predominant slow spike and wave with a "triphasic" appearance
 - Rhythmic 4-6 Hz centrotemporal activity
 - Posterior "notched" delta activity

Frontal slow spike and wave



Frontal triphasic spike and wave



Notched delta

Fp1 - F7 Ann Am F7 - T3√/\\ mm MANA $\sqrt{2}$ T3 - T5∕∽∖ i MMA ∩ Fp2 - F8 ∕∽ $\sim\sim$ my my man my my when F8 - T4 🗸 📈 vwiN MM MAY Т4-_Т6/ √ mmm M т6 - 02 ⁄⁄⁄ Junio water Fp1 - F3 AN MM M C3 - P3 ~~N F3 - 01 Fp2 - F4 m Mm. man mont \sim vinter \sim F4 - C4√∖ Nhm m C4 - P4 m $\sim \sim \sim$ F4 - 02 7 MAN Fz-Cz∫^ him 1 marth manyman m ------Cz - Pz

NON-EPILEPTIC MYOCLONUS

Non-epileptic Myoclonus

- In Larson et al (conducted in 2010) there were reports of prolonged "myoclonic seizures" in adults which typically began in adulthood (many of those reporting seizures in adulthood)
- These same events were also being reported more frequently in our clinic

Non-epileptic Myoclonus

Myoclonic seizures

- Common in Angelman syndrome (~15-40%) and are often the first seizure type reported; onset in early childhood
- Events are usually brief in duration typically seconds but can last up to a minute
- Children with myoclonic seizures typically have generalized spike and wave activity on interictal EEG and seizures captured on EEG are associated with spike and wave activity
- MGH clinic:
 - 17/185 (15%) had myoclonic seizures
 - Age of onset ~1-8 years (78% had onset before 5 years)


Non-epileptic Myoclonus

- Non-epileptic myoclonus
 - Age of onset is at puberty or later
 - Events last seconds to hours and can occur multiple times per day
 - There is no significant alteration of consciousness during the events and no post-ictal period
 - There is no associated regression or loss of skills
 - Events captured on EEG show no EEG changes
 - 12 individuals had prolonged EEG capturing events
 - 5 has inpatient video (3 MGH); 7 ambulatory (2 MGH)
 - All captured events and none had EEG correlate


Non-epileptic Myoclonus (Pollack et al, 2018)

- 187 individuals seen in clinic at time of study 87 were age 11+
- 35/87 (~40%) had non-epileptic myoclonus
- Prevalence increased with age, though most common age of onset was 11-20
- Longer events (>1 hour) were almost exclusively seen in those over age 20

Prevalence of NEM by age



Age of onset of NEM



SEIZURE TREATMENTS


Treat the Co-morbidities

- Epilepsy is associated with several medical, especially neurological and/or psychiatric symptoms (comorbid)
- Co-morbidities due to an underlying neuro-genetic syndrome are typically more frequent and severe
- Common issues that can worsen seizures
 - Poor sleep
 - Anxiety
 - Constipation
 - GI reflux
 - ADHD/impulsivity

Treatment options

- Medications
- Dietary Therapy
 - Ketogenic diet
 - Low glycemic index treatment
- Surgical options
 - VNS (not common)

Seizure treatment in AS



Broad spectrum meds (pre-2011)

- Ethosuximide (Zarontin)
- Benzodiazepines (Klonopin, others)
- Valproate (Depakote)
- Felbamate (Felbatol)
- Lamotrigine (Lamictal)
- Zonisamide (Zonegran)
- Topiramate (Topamax)
- Levetiracetam (Keppra)

Non-broad spectrum

- Worsen seizures in Angelman syndrome
 - Phenobarbital can be given IV for status
 - Phenytoin (Dilantin) can be given IV for status
 - Carbamazapine (Tegretol)
 - Oxcarbazepine (Trileptal)
- Likely do not worsen or improve seizures in AS
 - Gabapentin (Neurontin)
 - Pregabalin (Lyrica)

Newer Medications (since 2010)

- Clobazam (ONFI)
- Rufinamide (Banzel)
- Lacosimide (Vimpat)
- Ezogabine (Potiga) off the market
- Perampanel (Fycompa)
- Eslicarbazepine (Aptiom) likely not broad spectrum
- Brivaracetam (Briviact)
- CBD (Epidiolex)

Seizure Medications (Shaaya et al 2016)

Treatment	No change	<50% improved	50-90% improved	>90% improved
Valproic acid	0	0	8 (38.1%)	13 (61.9%)
Levetiracetam	0	0	5 (14.3%)	30 (85.7%)
Lamotrigine	0	0	2 (11.8%)	15 (88.2%)
Clobazam	2 (7.1%)	0	2 (7.1%)	24 (85.7%)
LGIT	0	1 (10%)	2 (20%)	7 (70%)

Seizure Medications (Shaaya et al, 2016)

Treatment	Average Dose (mg/kg/day)	Average course (months)	Adverse Effects
Valproic acid	26.6 (8-60)	56	66.6%
Levetiracetam	60.4 (6-200)	36	20%
Lamotrigine	6.6 (2.5-12)	58	23.5%
Clobazam	1.0 (0.2-2.1)	13	32%

Summary - medications

- Best options from case series:
 - Keppra
 - ONFI
 - Lamictal
- Other broad spectrum options:
 - Topamax
 - Zonegran
 - Klonopin
 - Felbatol
 - Zarontin

Summary - medications

- Broad spectrum with side effects
 - Depakote
- Newer broad spectrum
 - ONFI
 - Banzel
 - Vimpat
 - *Fycompa*
 - Briviact
 - Epidiolex
- Non-broad spectrum (OK for sleep and other purposes)
 - Neurontin/Lyrica

Summary - medications

- Non-broad spectrum
- Worsen seizures
 - Tegretol
 - Trileptal
 - Aptiom (may be more broad spectrum?)
- Worsen seizures but option for convulsive status
 - Dilantin
 - Phenobarbital

CBD

- Marijuana is divided into THC (psychoactive portion) and cannabinoids
 CBD (non-psychoactive portion)
- CBD was recently shown to be effective for treating refractory seizures in children
- Side effects were minimal and included sedation and loose stool
- No specific studies have been performed in an Angelman syndrome population, but there is anecdotal evidence that it can be effective
- Some families have reported significant improvement in non-epileptic myoclonus; others have felt that it helped sleep and/or anxiety

Ketogenic Diet

- Used since 1920's but evidence dates back much earlier
- Exact mechanism of action is not known
- High fat diet (90%) that allows <10 gm carbohydrate per day
- Typical ratio of fat to protein/carbs is 4:1 but can be less
- Initiate with a short hospital stay (fasting no longer used) with close laboratory monitoring
- Need to monitor for ketosis/acidosis and treat with poly-cytra if needed
- Carbonic anhydrase inhibitors (Topamax, Zonegran) can worsen acidosis and increase risk of renal stones
- Typically get hyperlipidemia and decreased bone density, supplement with Vitamin D, Calcium and multivitamins; also carnitine may be needed

Low Glycemic Index Treatment

- Based on the "glycemic index" foods (raises blood glucose)
- Allows for 40-60 g carbohydrates per day
 - 10% carbs; 20-30% protein; 60-70% fat
- No need for admission; monitoring less strict but still needed
- Meals based on percentages above and caloric needs
- Compliance better than ketogenic as less restrictive
- Efficacy not quite as good as ketogenic so can convert for better control
 - 1/3 not effective or not tolerated
 - 1/3 50-90% reduction in seizures
 - 1/3 >90% reduction in seizures or seizure free
 - Can take 2 weeks to 2-3 months to see effects

LGIT trial in AS

- LGIT prospective trial 6 children with AS
- After 4 months:
 - 4 children >90% seizure-free
 - 1 child 50-90% seizure-free
 - 1 child <50% seizure free
- After 1 year (5 still on LGIT)
 - All 5 children >90% seizure-free
- Since trial have placed ~23 children on LGIT
 - Thibert et al. 2012

LGIT in AS (MGH – Grocott et al 2017 Ep and Behav)

Overall – 23+ children/adults have been on the LGIT

- Daily seizures (5) all improved with 1 seizure-free except illness
- Weekly seizures (3) all improved with 1 seizure-free except illness
- Monthly seizures (2) both seizure-free, 1 except for illness
- Seizures only when ill (3) 2 were similar and 1 seizure-free
- Only NCSE (1) still had NCSE
- Well controlled (1) stayed well controlled and cut medications

Overall themes

- LGIT very effective in Angelman syndrome
- Seizure control often achieved with >60 g per carbohydrates
- Illness and NCSE are the 2 situations where diet is less effective

Surgical options

- Resective surgery
 - Removal of a portion of the brain causing the seizures
 - Not an option in Angelman syndrome
- Vagal nerve stimulator (VNS)
 - VNS generator implanted in chest wall and bipolar lead wrapped around left vagus nerve
 - Pulse sent to vagus nerve which transmits signals to the brain though exact mechanism is unknown
 - Generator can be reprogrammed to change current voltage, pulse width, signal frequency, on time and off time
 - Studies have shown 25-60% have experienced >50% seizure reduction with VNS
 - Typical side effects include altered voice, cough, paresthesia, dyspnea
 - Surgical complications and systemic effects rare

Non-epileptic Myoclonus treatment

Medication	Worse or no change	<50% improved	50-90% improved	>90% improved
Levetiracetam N=10	0	5 (50%)	2 (20%)	3 (30%)
Clobazam N=9	2 (22%) Fatigue	4 (44%)	1 (10%)	2 (20%)
Clonazepam N=5	1 (20%) Fatigue	0	2 (40%)	2 (40%)

Non-epileptic Myoclonus treatment

Best treatment is to treat triggers!

- Poor sleep
- GI dysfunction (constipation/reflux)
- Anxiety
- Pain (GI or orthopedic)

Treatment of NCSE/LGS (Worden et al, 2018)

- 13 children (25 episodes of NCSE) treated outpatient with diazepam (Valium) 0.3-0.5 mg/kg/day divided into 2 doses – with doses decreased in half every 2-3 days
- Often an underlying cause is present, such as infection, poor sleep, etc. (14/25 episodes), so important to treat underlying cause as well
- Oral diazepam alone was effective in 20/25 (80%) of events
- If Valium fails, can use 6 week tapering course of prednisone (or prednisolone) +/- IV administration prior to oral medications
- Only 3/25 (12%) episodes required hospitalization
- No significant side effects (fatigue in 2 children)

Treatment summary

- Assess for seizure triggers and/or comorbidities and treat as needed
 - Especially in non-epileptic myoclonus
- Medications or dietary therapy first line if treatment needed
 - LGIT especially effective in AS, can be used first line
- If medication use broad spectrum medication
 - Keppra, ONFI, Lamictal worked best in MGH study
 - Depakote is effective but has significant side effect rate in AS

MGH/LC Angelman Syndrome Clinic

- Neurology/Epilepsy Ron Thibert
- Psychiatry Chris Keary
- GI Kriston Ganguli
- Dietary therapy Heidi Pfeifer
- Neuropsychology Amy Morgan
- Sleep medicine Ken Sassower
- NP Amanda Tourjee
- Nursing Katrina Styles
- Behavioral therapy Nicole Simon
- Clinic Coordinator Kim Parkin
- Research Intern Stephanie Yemane

MGH Angelman Syndrome Clinic

